Cabozantinib
Sign in to save this workspacePrimary targets: RET, KDR_VEGFR2 · FDA status: FDA Approved
Selectivity scorecard
KISS
92.73
Gini
0.751
CATDS
0.014
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Cabozantinib. Strongest target: DDR2 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | DDR2 | 100.0% | 0.0% |
| 2 | TRKB | 100.0% | 0.0% |
| 3 | DDR1 | 100.0% | 0.0% |
| 4 | HIPK4 | 100.0% | 0.0% |
| 5 | BRK | 99.5% | 0.5% |
| 6 | C_MET | 99.2% | 0.8% |
| 7 | RET | 97.5% | 2.5% |
| 8 | LCK | 97.5% | 2.5% |
| 9 | C_MER | 97.0% | 3.0% |
| 10 | YSK4_MAP3K19 | 96.8% | 3.2% |
| 11 | ROS_ROS1 | 96.0% | 4.0% |
| 12 | AXL | 95.9% | 4.1% |
| 13 | EPHA6 | 95.7% | 4.3% |
| 14 | FLT4_VEGFR3 | 95.2% | 4.8% |
| 15 | KDR_VEGFR2 | 95.0% | 5.0% |
| 16 | FLT3 | 95.0% | 5.0% |
| 17 | RIPK3 | 94.5% | 5.5% |
| 18 | EPHB2 | 94.5% | 5.5% |
| 19 | EPHA4 | 94.5% | 5.5% |
| 20 | LOK_STK10 | 94.3% | 5.7% |
Selectivity landscape
Where Cabozantinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Cabozantinib.
Annotations
Sign in to read and post annotations.
Loading…